ABSTRACT
Recombinant human parathyroid hormone (1-34) (rhPTH 1-34), teriparatide, is a class of anabolic therapy for treating severe osteoporosis. Although plasma cell dyscrasias are excluded among the known side effects of teriparatide treatment, their association in the form of case reports has been reported. PTH 1-34 stimulates osteoblasts and indirectly stimulates receptor activator of nuclear factor kappa-B ligand (RANKL), RANK and IL-6 with osteoclast stimulation. There are relationships between RANKL/OPG system and osteoclast and osteoblast activity in multiple myeloma. We report a case with multiple myeloma who developed malignant myeloma after teriparatide treatment.
References
1
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014;25:2359-81.
2
Cohen A, Shane E. Treatment of Premenopausal Women with Low Bone Mineral Density. Curr Osteoporos Rep 2008;6:39-46.
3
Martinez-Morillo M, Grados D, Holgado S. Premenopausal Osteoporosis: How to Treat? Reumatol Clin 2012;8:93-7.
4
Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
5
Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 2012;27:2419-28.
6
Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal change in rats given Daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21.
7
Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007;92:4514-21.
8
Buxton EC, Yaow, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinal Metab 2004;89:3332-6.
9
Liang JD, Hock JM, Sandusky GE, Santerre RF, Onyia JE. Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH1-34. Calcif Tissue Int 1999;65:369-73.
10
Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Do human myeloma cells directly produce the receptor activator of nuclear factor kB ligand (RANKL) or induce RANKL in the bone marrow microenvironment? Cancer Res 2004;64:772-5.
11
Stone MJ, Lieberman ZH, Chakmakjian ZH, Matthews JL. Coexistent myeloma and primary hyperparathyroidism. JAMA 1982;247:823-4.
12
Arnulf B, Bengoufa D, Sarfati E, Toubert ME, Meignin V, Brouet JC, et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: A prospective study. Arch Intern Med 2002;162:464-7.
13
Treon SP, Anderso KC. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Hematol 1998;5:42-8.
14
Koski AM, Sikiö A, Forslund T. Teriparatide treatment complicated by malignant myeloma. BMJ Case Rep 2010;2010:bcr0120102681.
15
Mumford ER, Raffles S, Reynolds P. Coexistent osteoporosis and multiple myeloma: when to investigate further in osteoporosis. BMJ Case Rep 2015;2015:bcr2015210896.